Reoperation does not provide a survival advantage in patients with recurrent Glioblastoma treated with irinotecan/bevacizumab treatment

被引：2
|
作者：
Sever, Ozlem Nuray [1 ]
Oktay, Kadir [2 ]
Guzel, Ebru [3 ]
Kaya, Vildan [5 ]
Guzel, Aslan [2 ]
Yildirim, Mustafa [4 ]
机构：
[1] Gaziantep Univ, Sch Med, Dept Internal Med & Med Oncol, Gaziantep, Turkey
[2] Med Pk Gaziantep Hosp, Dept Neurosurg, Gaziantep, Turkey
[3] Med Pk Gaziantep Hosp, Dept Radiol, Gaziantep, Turkey
[4] Med Pk Gaziantep Hosp, Dept Med Oncol, Gaziantep, Turkey
[5] Medstar Antalya Hosp, Dept Radiat Oncol, Antalya, Turkey
来源：
INDIAN JOURNAL OF CANCER | 2021年 / 58卷 / 01期
关键词：
Glioblastoma; recurrence; reoperation; survival; PROGNOSTIC-FACTORS; REPEATED SURGERY; PHASE-III; BEVACIZUMAB; TRIAL; RADIOTHERAPY; TEMOZOLOMIDE; COMBINATION; MULTIFORME; LOMUSTINE;
D O I：
10.4103/ijc.IJC_758_18
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Background: Treatment options for recurrent glioblastoma (GBM) have limited efficacy. Although reoperation is useful for both the confirmation of the diagnosis of recurring disease and the relief of the symptoms, its effect on survival is unknown. The aim of this study was to evaulate the impact of second surgery in recurrent GBM. Methods: Patients with GBM followed in our center between January 2015 and April 2018 were analyzed retrospectively based on the treatment options. Results: 25 patients diagnosed with recurrent GBM were analyzed. Ten patients (40%) were treated with chemotherapy following reoperation, and 15 patients (60%) were treated with only chemotherapy. No benefits of reoperation were observed in the univariate analysis. Conclusion: The second surgery in recurrent GBM has limited effect in clinical course.
引用
收藏
页码：91 / 95
页数：5
相关论文
共 50 条
  • [1] MCQs on "Reoperation does not provide a survival advantage in patients with recurrent Glioblastoma treated with irinotecan/bevacizumab treatment"
    Darling, H. S.
    Jaiswal, Pradeep
    Lohia, Nishant
    Tiwari, Nishant R.
    [J]. INDIAN JOURNAL OF CANCER, 2021, 58 (01) : 96 - 97
  • [2] BEVACIZUMAB AND IRINOTECAN IN THE TREATMENT OF PATIENTS WITH RECURRENT GLIOBLASTOMA
    Naskhletashvili, D. R.
    Gorbounova, V.
    Bychkov, M.
    Bekyashev, A.
    Karakhan, V.
    Aloshin, V.
    Fu, R.
    Moskvina, E.
    [J]. NEURO-ONCOLOGY, 2012, 14 : 59 - 59
  • [3] Recurrent glioblastoma: Does the timing of bevacizumab treatment impact survival?
    Sakruti, Susmita
    Randhawa, Jaakirat Singh
    Griffith, Sandra D.
    Stevens, Glen
    Peereboom, David M.
    Ahluwalla, Manmeet Singh
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [4] Development and validation of a prognostic model for recurrent glioblastoma patients treated with bevacizumab and irinotecan
    Urup, Thomas
    Dahlrot, Rikke Hedegaard
    Grunnet, Kirsten
    Christensen, Ib Jarle
    Michaelsen, Signe Regner
    Toft, Anders
    Larsen, Vibeke Andree
    Broholm, Helle
    Kosteljanetz, Michael
    Hansen, Steinbjorn
    Poulsen, Hans Skovgaard
    Lassen, Ulrik
    [J]. ACTA ONCOLOGICA, 2016, 55 (04) : 418 - 422
  • [5] Radiographic evaluation of recurrent glioblastoma multiforme (GBM) in patients treated with bevacizumab and irinotecan
    Andre, J.
    Spearman, K.
    Lu, S.
    Hwang, S.
    Dorsett, L.
    Raval, S.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [6] Radiographic evaluation of recurrent glioblastoma multiforme (gbm) in patients treated with bevacizumab and irinotecan
    Andre, Jalal
    Spearman, Kenneth
    Lu, Stanley
    Raval, Sumul
    [J]. NEURO-ONCOLOGY, 2007, 9 (04) : 575 - 575
  • [7] Response as a predictor of survival in patients with recurrent glioblastoma treated with bevacizumab
    Prados, Michael
    Cloughesy, Timothy
    Samant, Meghna
    Fang, Liang
    Wen, Patrick Y.
    Mikkelsen, Tom
    Schiff, David
    Abrey, Lauren E.
    Yung, W. K. Alfred
    Paleologos, Nina
    Nicholas, Martin K.
    Jensen, Randy
    Vredenburgh, James
    Das, Asha
    Friedman, Henry S.
    [J]. NEURO-ONCOLOGY, 2011, 13 (01) : 143 - 151
  • [8] Bevacizumab in combination with irinotecan for patients with recurrent glioblastoma multiforme
    Schiff, David
    Purow, Benjamin
    [J]. NATURE CLINICAL PRACTICE ONCOLOGY, 2008, 5 (04): : 186 - 187
  • [9] Bevacizumab in combination with irinotecan for patients with recurrent glioblastoma multiforme
    David Schiff
    Benjamin Purow
    [J]. Nature Clinical Practice Oncology, 2008, 5 : 186 - 187
  • [10] Bevacizumab and irinotecan in patients with recurrent glioblastoma multiforme (GBM)
    Raval, Sumul N.
    Rule, Amy
    Hwang, Shirley S.
    [J]. NEURO-ONCOLOGY, 2006, 8 (04) : 482 - 482
12345